CN113318123A - 用于预防和/或改善肺炎的含分子态氢组合物 - Google Patents
用于预防和/或改善肺炎的含分子态氢组合物 Download PDFInfo
- Publication number
- CN113318123A CN113318123A CN202110202539.5A CN202110202539A CN113318123A CN 113318123 A CN113318123 A CN 113318123A CN 202110202539 A CN202110202539 A CN 202110202539A CN 113318123 A CN113318123 A CN 113318123A
- Authority
- CN
- China
- Prior art keywords
- pneumonia
- hydrogen
- vol
- gas
- molecular hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 title claims abstract description 127
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 208000024891 symptom Diseases 0.000 claims abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 63
- 239000001257 hydrogen Substances 0.000 claims description 63
- 239000007789 gas Substances 0.000 claims description 36
- 239000007788 liquid Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 8
- 201000001178 Bacterial Pneumonia Diseases 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 206010035737 Pneumonia viral Diseases 0.000 claims description 5
- 208000009421 viral pneumonia Diseases 0.000 claims description 5
- 230000002538 fungal effect Effects 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 206010016256 fatigue Diseases 0.000 claims description 3
- 206010008479 Chest Pain Diseases 0.000 claims description 2
- 206010011224 Cough Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 208000000059 Dyspnea Diseases 0.000 claims description 2
- 206010013975 Dyspnoeas Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 claims description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 2
- 201000007100 Pharyngitis Diseases 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 208000036071 Rhinorrhea Diseases 0.000 claims description 2
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 230000004217 heart function Effects 0.000 claims description 2
- 230000003907 kidney function Effects 0.000 claims description 2
- 201000002364 leukopenia Diseases 0.000 claims description 2
- 231100001022 leukopenia Toxicity 0.000 claims description 2
- 230000004199 lung function Effects 0.000 claims description 2
- 230000008693 nausea Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010041232 sneezing Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 210000004072 lung Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 208000029523 Interstitial Lung disease Diseases 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 241000233870 Pneumocystis Species 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- -1 etc.) Chemical compound 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- 201000000317 pneumocystosis Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010005098 Blastomycosis Diseases 0.000 description 2
- 241001678559 COVID-19 virus Species 0.000 description 2
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 201000002563 Histoplasmosis Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005868 electrolysis reaction Methods 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037765 Radiation pneumonitis Diseases 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000009876 antimalignant effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910012375 magnesium hydride Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020-046965 | 2020-02-28 | ||
| JP2020046965 | 2020-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113318123A true CN113318123A (zh) | 2021-08-31 |
Family
ID=77414489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110202539.5A Pending CN113318123A (zh) | 2020-02-28 | 2021-02-23 | 用于预防和/或改善肺炎的含分子态氢组合物 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20210268017A1 (https=) |
| JP (1) | JP2021178877A (https=) |
| CN (1) | CN113318123A (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7436763B2 (ja) | 2021-08-23 | 2024-02-22 | ＭｉＺ株式会社 | 肺炎を予防および／または改善するための分子状水素含有組成物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1228706A (zh) * | 1996-08-27 | 1999-09-15 | 梅塞尔·格里斯海姆有限公司 | 含氢的药物产品 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5612743B1 (ja) * | 2013-09-01 | 2014-10-22 | 河村 隆夫 | 高濃度水素混合ガス呼吸システム |
| JP2016000081A (ja) * | 2014-06-11 | 2016-01-07 | 日本光電工業株式会社 | 水素治療装置及び水素治療方法 |
| JP2019506259A (ja) * | 2015-12-11 | 2019-03-07 | ベロ バイオテック エルエルシー | 線維症に対処するために一酸化窒素を含むガスを投与するための方法及び装置 |
| EP3397331A4 (en) * | 2015-12-28 | 2019-08-21 | Vero Biotech LLC | METHOD AND APPARATUS FOR ADMINISTERING NITRIC OXIDE WITH ADDITIONAL MEDICAMENTS |
| JP6628449B1 (ja) * | 2018-07-30 | 2020-01-08 | 国立大学法人名古屋大学 | 閉塞性気道疾患の抑制又は軽減のための組成物 |
-
2021
- 2021-02-23 CN CN202110202539.5A patent/CN113318123A/zh active Pending
- 2021-02-25 US US17/185,450 patent/US20210268017A1/en not_active Abandoned
- 2021-08-23 JP JP2021135592A patent/JP2021178877A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1228706A (zh) * | 1996-08-27 | 1999-09-15 | 梅塞尔·格里斯海姆有限公司 | 含氢的药物产品 |
Non-Patent Citations (2)
| Title |
|---|
| HUIYING LIU等: "COMBINATION THERAPY WITH NITRIC OXIDE AND MOLECULAR HYDROGEN IN A MURINE MODEL OF ACUTE LUNG INJURY", 《SHOCK》, vol. 43, no. 5, pages 504 - 511, XP055392201, DOI: 10.1097/SHK.0000000000000316 * |
| KELIANG XIE等: "MOLECULAR HYDROGEN AMELIORATES LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INJURY IN MICE THROUGH REDUCING INFLAMMATION AND APOPTOSIS", 《SHOCK》, vol. 37, no. 5, pages 548 - 555 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20210268017A1 (en) | 2021-09-02 |
| JP2021178877A (ja) | 2021-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4585765B2 (ja) | 壊死性腸炎の治療方法 | |
| JP2022159439A (ja) | 術後回復を促進するための分子状水素含有組成物 | |
| JP7312341B2 (ja) | パーキンソン病症状の改善又は予防のための組成物 | |
| JP6972449B2 (ja) | 炎症性腸疾患を予防および／または改善するための分子状水素含有組成物 | |
| JP2022065119A (ja) | 薬の副作用、薬の副作用に関連する症状、および／または、治療に伴う副作用を予防および／または改善するための組成物 | |
| JP6628449B1 (ja) | 閉塞性気道疾患の抑制又は軽減のための組成物 | |
| JP2020002090A (ja) | 水素を含む癌性疼痛の抑制もしくは軽減のための組成物 | |
| CN113318123A (zh) | 用于预防和/或改善肺炎的含分子态氢组合物 | |
| JP2021138678A (ja) | 遺伝子疾患を予防および／または改善するための分子状水素含有組成物 | |
| JP7414202B2 (ja) | ヒトの肺がん時の肺機能の維持、および／または、ヒトの肺がんに起因する肺機能の低下を改善するための分子状水素含有組成物 | |
| JP7455293B2 (ja) | 脳卒中後の後遺症改善のための組成物 | |
| JP2021152015A (ja) | 脳炎および／または髄膜炎と当該脳炎および／または髄膜炎に関連する症状を予防および／または改善するための分子状水素含有組成物 | |
| JP7436763B2 (ja) | 肺炎を予防および／または改善するための分子状水素含有組成物 | |
| JP7502584B2 (ja) | 骨粗しょう症の予防又は改善をするための分子状水素含有組成物 | |
| JP2022049676A (ja) | 慢性炎症を予防および／または改善するための分子状水素含有組成物 | |
| US20230256007A1 (en) | Composition for improving sequelae of viral infection and/or reducing worsening of symptoms | |
| JP7220339B1 (ja) | 突発性難聴の改善および／または症状の悪化を抑制するのための組成物 | |
| JP7409586B2 (ja) | 筋痛性脳脊髄炎／慢性疲労症候群（ｍｅ／ｃｆｓ）および／または線維筋痛症（ｆｍ）の改善および／または症状の悪化を抑制するのための組成物 | |
| CN117177758A (zh) | 一种施用一氧化氮气体的方法 | |
| JP2024072231A (ja) | 筋萎縮性側索硬化症（ａｌｓ）および／またはａｌｓに関連する症状を予防、または、改善するのための組成物および方法 | |
| JP2023143735A (ja) | 臓器特異的自己免疫疾患を予防および／または改善するのための組成物および方法 | |
| JP2023039876A (ja) | 痛風の改善および／または症状の悪化を抑制するのための組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210831 |